CN106822133A - 一种治疗急性腹泻的西药组合物 - Google Patents
一种治疗急性腹泻的西药组合物 Download PDFInfo
- Publication number
- CN106822133A CN106822133A CN201611171780.1A CN201611171780A CN106822133A CN 106822133 A CN106822133 A CN 106822133A CN 201611171780 A CN201611171780 A CN 201611171780A CN 106822133 A CN106822133 A CN 106822133A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- medicine compound
- acid
- acute diarrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 201000009840 acute diarrhea Diseases 0.000 title claims abstract description 35
- DOFJNFPSMUCECH-UHFFFAOYSA-N Demethylnobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 DOFJNFPSMUCECH-UHFFFAOYSA-N 0.000 claims abstract description 38
- DEBDFZGNZTYPMF-NZBPQXDJSA-N Isocurcumenol Chemical compound C=C1C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 DEBDFZGNZTYPMF-NZBPQXDJSA-N 0.000 claims abstract description 24
- 239000002253 acid Substances 0.000 claims abstract description 24
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 claims abstract description 19
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 19
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 19
- 241000018646 Pinus brutia Species 0.000 claims abstract description 19
- WWBNBPSEKLOHJU-CEOIDQJPSA-N Sinalbin Natural products S(=O)(=O)(O/N=C(\S[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/Cc1ccc(O)cc1)O WWBNBPSEKLOHJU-CEOIDQJPSA-N 0.000 claims abstract description 19
- 241001251949 Xanthium sibiricum Species 0.000 claims abstract description 19
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims abstract description 19
- 229960000782 bismuth subsalicylate Drugs 0.000 claims abstract description 19
- 238000006356 dehydrogenation reaction Methods 0.000 claims abstract description 19
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000002596 lactones Chemical class 0.000 claims abstract description 19
- WWBNBPSEKLOHJU-RFEZBLSLSA-N sinalbin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N/OS(O)(=O)=O)CC1=CC=C(O)C=C1 WWBNBPSEKLOHJU-RFEZBLSLSA-N 0.000 claims abstract description 19
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 claims abstract description 18
- JXRYDOZRPYFBKO-UHFFFAOYSA-N 3,4-dimethoxy-cinnamic acidmethyl ester Natural products COC(=O)C=CC1=CC=C(OC)C(OC)=C1 JXRYDOZRPYFBKO-UHFFFAOYSA-N 0.000 claims abstract description 18
- GYKXKOROZFUMIC-UHFFFAOYSA-N 4-[(4-carbamoylphenyl)carbamoylamino]benzenesulfonyl chloride Chemical compound C1=CC(C(=O)N)=CC=C1NC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GYKXKOROZFUMIC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 18
- OCNYGKNIVPVPPX-HWKANZROSA-N methyl caffeate Chemical compound COC(=O)\C=C\C1=CC=C(O)C(O)=C1 OCNYGKNIVPVPPX-HWKANZROSA-N 0.000 claims abstract description 18
- RPNLENLGIIEIJQ-KECSMNPBSA-N charantin A Natural products CO[C@H]1C=C2[C@@H](CC[C@H](O)C2(C)C)[C@@]3(CC[C@]4(C)[C@H](CC[C@@]4(C)[C@H]13)[C@H](C)[C@@H](O)C=C(C)C)C=O RPNLENLGIIEIJQ-KECSMNPBSA-N 0.000 claims abstract description 14
- VDWSYBFEQXWINA-UHFFFAOYSA-N Martinoside Natural products C1=C(O)C(OC)=CC=C1CCOC1C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(OC(=O)C=CC=2C=C(O)C(OC)=CC=2)C(CO)O1 VDWSYBFEQXWINA-UHFFFAOYSA-N 0.000 claims abstract description 13
- WLWAYPFRKDSFCL-CNMJWYMJSA-N [(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC=C1CCO[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)[C@@H](CO)O1 WLWAYPFRKDSFCL-CNMJWYMJSA-N 0.000 claims abstract description 13
- RLGRBYHBNWLGER-UHFFFAOYSA-N cistanoside D Natural products C1=C(O)C(OC)=CC(CCOC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(OC(=O)C=CC=3C=C(OC)C(O)=CC=3)C(CO)O2)O)=C1 RLGRBYHBNWLGER-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZMYQRHSOVRDQDL-NSWBACJASA-N leucosceptoside A Natural products COc1cc(C=CC(=O)O[C@@H]2[C@@H](CO)O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@H]2O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)ccc1O ZMYQRHSOVRDQDL-NSWBACJASA-N 0.000 claims abstract description 13
- WLWAYPFRKDSFCL-AYPSUWEUSA-N martynoside Natural products COc1ccc(CCO[C@@H]2O[C@H](CO)[C@@H](OC(=O)C=Cc3ccc(O)c(OC)c3)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H]2O)cc1O WLWAYPFRKDSFCL-AYPSUWEUSA-N 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- IEDDICKFTXIWIP-UHFFFAOYSA-N Ganoderic acid D Natural products CC(CC(=O)CCC1CC(=O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O IEDDICKFTXIWIP-UHFFFAOYSA-N 0.000 claims abstract description 6
- VVXZWUASDACSNQ-UHFFFAOYSA-N ganoderic acid C Natural products CC12CCC(O)C(C)(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CC(=O)CC(C)C(O)=O)C)CC(O)C21 VVXZWUASDACSNQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 22
- -1 aboktal Chemical compound 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- BTYTWXWAFWKSTA-BIGSUGRTSA-N 12-Deacetylganoderic acid H Natural products O=C(O)[C@@H](CC(=O)C[C@@H](C)[C@@H]1[C@@]2(C)[C@H](O)C(=O)C=3[C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC(=O)C=3[C@]2(C)C(=O)C1)C BTYTWXWAFWKSTA-BIGSUGRTSA-N 0.000 claims description 7
- IDCKVKLARBGJJT-JTQCLAQKSA-N Ganoderic Acid C6 Natural products C[C@H](CC=O)CC(=O)C[C@@H](C)[C@H]1CC(=O)[C@@]2(C)C3=C(C(=O)[C@@H](O)[C@]12C)[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC3=O IDCKVKLARBGJJT-JTQCLAQKSA-N 0.000 claims description 7
- BTYTWXWAFWKSTA-YBFNEQRTSA-N Ganoderic Acid C6 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)[C@@H](O)[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C BTYTWXWAFWKSTA-YBFNEQRTSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims 1
- 235000014375 Curcuma Nutrition 0.000 claims 1
- 244000164480 Curcuma aromatica Species 0.000 claims 1
- 240000009138 Curcuma zedoaria Species 0.000 claims 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 229940074360 caffeic acid Drugs 0.000 claims 1
- 235000004883 caffeic acid Nutrition 0.000 claims 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 1
- 150000002085 enols Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000019509 white turmeric Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- HICAMHOOTMOHPA-HIFRSBDPSA-N (5r,6r)-6-ethenyl-3,6-dimethyl-5-prop-1-en-2-yl-5,7-dihydro-4h-1-benzofuran Chemical compound C1[C@@](C=C)(C)[C@@H](C(=C)C)CC2=C1OC=C2C HICAMHOOTMOHPA-HIFRSBDPSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HICAMHOOTMOHPA-UHFFFAOYSA-N Isofuranogermacren Natural products C1C(C=C)(C)C(C(=C)C)CC2=C1OC=C2C HICAMHOOTMOHPA-UHFFFAOYSA-N 0.000 description 6
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 6
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 6
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 241000219112 Cucumis Species 0.000 description 5
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010012742 Diarrhoea infectious Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000207961 Sesamum Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 2
- 229930182735 Ganoderic acid Natural products 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 241000607764 Shigella dysenteriae Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010017914 Gastroenteritis salmonella Diseases 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗急性腹泻的西药组合物,所述治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯8‑12份、苦瓜苷A 15‑19份、白芥子苷3‑8份、地黄苷7‑12份、次水杨酸铋0.5‑0.7份、甲氟哌酸6‑9份、去甲基川陈皮素16‑22份、去甲基蟛蜞内酯7‑15份、石蒜碱盐酸盐2‑4份、异莪术烯醇2‑4份、3‑氢化去氢松苓酸2‑4份、灵芝酸C6 2‑4份、异银杏素5‑10份。本发明药物根据急性腹泻的认识机理对原料成分进行严格挑选,从而达到全面康复的目的,具有起效快、作用稳定、携带服用方便、长期服用无毒副作用的特点。
Description
技术领域
本发明涉及一种医药制备领域,具体是一种治疗急性腹泻的西药组合物。
背景技术
肠黏膜的分泌旺盛与吸收障碍、肠蠕动过快,致排便频率增加,粪质稀薄,含有异常成分者,称为腹泻。急性腹泻起病急骤,每天排便可达10次以上,粪便量多而稀薄,排便时常伴腹鸣、肠绞痛或里急后重。感染是腹泻最常见的原因。在发展中国家,合并脱水及营养不良的感染性腹泻是可能致死的主要原因,即使在发达国家急性腹泻也可演变为胃肠急症。例如霍乱弧菌或难辨梭状芽孢杆菌感染,尤其是伴有低血压、休克、肾衰竭、肠穿孔或出血时,可危及生命。
临床上除腹泻外,一般都有发热、腹痛及白细胞增多等表现。这些临床表现是共同的,对肠道感染的部位及病原菌均无诊断价值,因此,需首先鉴别是小肠或结肠感染。小肠感染性腹泻的特点是脐周或右下腹为阵发性痛,且伴有腹胀或肠鸣,腹泻每天5~10次,粪便量多呈稀水便,混有泡沫及未消化食物残渣,严重感染者为稀水血便,排便前腹痛,便后腹痛可减轻或消失而有舒适感。结肠感染性腹泻的腹痛,常在下腹或左下腹部,一般不伴肠鸣,腹泻频繁,较小肠感染性腹泻次数显著增多,粪便量少,呈脓血便外观,有里急后重及下坠感。小肠感染性腹泻多见于葡萄球菌食物中毒或沙门菌属肠炎,而结肠感染性腹泻常由志贺菌或其他痢疾杆菌所引起。
发明内容
本发明的目的在于提供一种治疗急性腹泻的西药组合物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯8-12份、苦瓜苷A 15-19份、白芥子苷3-8份、地黄苷7-12份、次水杨酸铋0.5-0.7份、甲氟哌酸6-9份、去甲基川陈皮素16-22份、去甲基蟛蜞内酯7-15份、石蒜碱盐酸盐2-4份、异莪术烯醇2-4份、3-氢化去氢松苓酸2-4份、灵芝酸C62-4份、异银杏素5-10份。
作为本发明进一步的方案:所述治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯9-11份、苦瓜苷A 16-18份、白芥子苷5-7份、地黄苷8-11份、次水杨酸铋0.5-0.7份、甲氟哌酸6-9份、去甲基川陈皮素18-21份、去甲基蟛蜞内酯8-12份、石蒜碱盐酸盐2-4份、异莪术烯醇2-4份、3-氢化去氢松苓酸2-4份、灵芝酸C62-4份、异银杏素6-8份。
作为本发明进一步的方案:所述治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯10份、苦瓜苷A 17份、白芥子苷6份、地黄苷10份、次水杨酸铋0.6份、甲氟哌酸8份、去甲基川陈皮素20份、去甲基蟛蜞内酯10份、石蒜碱盐酸盐3份、异莪术烯醇3份、3-氢化去氢松苓酸3份、灵芝酸C6 3份、异银杏素7份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合4-8min,控制RSD≤5%,混合后压片并低温干燥,温度控制在4-8℃,包装即得治疗急性腹泻的西药组合物。
作为本发明进一步的方案:具体步骤中混合6min。
作为本发明进一步的方案:具体步骤中温度控制在6℃。
与现有技术相比,本发明的有益效果是:
本发明药物根据急性腹泻的认识机理对原料成分进行严格挑选,从而达到全面康复的目的,具有起效快、作用稳定、携带服用方便、长期服用无毒副作用的特点。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯8份、苦瓜苷A 15份、白芥子苷3份、地黄苷7份、次水杨酸铋0.5份、甲氟哌酸6份、去甲基川陈皮素16份、去甲基蟛蜞内酯7份、石蒜碱盐酸盐2份、异莪术烯醇2份、3-氢化去氢松苓酸2份、灵芝酸C6 2份、异银杏素5份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合6min,控制RSD≤5%,混合后压片并低温干燥,温度控制在6℃,包装即得治疗急性腹泻的西药组合物。
实施例2
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯9份、苦瓜苷A 16份、白芥子苷5份、地黄苷8份、次水杨酸铋0.5份、甲氟哌酸6份、去甲基川陈皮素18份、去甲基蟛蜞内酯8份、石蒜碱盐酸盐2份、异莪术烯醇2份、3-氢化去氢松苓酸2份、灵芝酸C6 2份、异银杏素6份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合4min,控制RSD≤5%,混合后压片并低温干燥,温度控制在4℃,包装即得治疗急性腹泻的西药组合物。
实施例3
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯10份、苦瓜苷A 17份、白芥子苷6份、地黄苷10份、次水杨酸铋0.6份、甲氟哌酸8份、去甲基川陈皮素20份、去甲基蟛蜞内酯10份、石蒜碱盐酸盐3份、异莪术烯醇3份、3-氢化去氢松苓酸3份、灵芝酸C6 3份、异银杏素7份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合6min,控制RSD≤5%,混合后压片并低温干燥,温度控制在6℃,包装即得治疗急性腹泻的西药组合物。
实施例4
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯11份、苦瓜苷A 18份、白芥子苷7份、地黄苷11份、次水杨酸铋0.7份、甲氟哌酸9份、去甲基川陈皮素21份、去甲基蟛蜞内酯12份、石蒜碱盐酸盐4份、异莪术烯醇4份、3-氢化去氢松苓酸4份、灵芝酸C6 4份、异银杏素8份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合8min,控制RSD≤5%,混合后压片并低温干燥,温度控制在8℃,包装即得治疗急性腹泻的西药组合物。
实施例5
一种治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯12份、苦瓜苷A 19份、白芥子苷8份、地黄苷12份、次水杨酸铋0.7份、甲氟哌酸9份、去甲基川陈皮素22份、去甲基蟛蜞内酯15份、石蒜碱盐酸盐4份、异莪术烯醇4份、3-氢化去氢松苓酸4份、灵芝酸C6 4份、异银杏素10份。
一种治疗急性腹泻的西药组合物的制备方法,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合8min,控制RSD≤5%,混合后压片并低温干燥,温度控制在8℃,包装即得治疗急性腹泻的西药组合物。
药理学试验
1、急性毒性试验
以本发明实施例3制得的西药组合物为试验,采用灌胃给药方式,在24h内连续给药2次,每次间隔6h,每次给药500mg/kg药量,每天累积药物总量达1000mg药物/kg,相当于人临床用量的100倍。给药后7d内,小鼠活动、进食、排泄均正常,生长良好,毛色光亮,其平均体重均随实验时间的延长而增加。第8d处死后解剖每只小鼠,肉眼观察心、肝、脾、肺、肾、脑、胸腺、胃、肠等均未发现颜色及形态异常,未能测出半数致死量(LD50)。结果表明:本发明西药组合物无急性毒性反应。
2、长期毒性试验
以本发明实施例3制得的西药组合物为试验,采用灌胃给药方式,将本发明西药组合物分为低剂量、中剂量、高剂量三组,各组的药物用量分别为100、200、300mg药物/kg/d,相当于临床剂量的10、20、30倍。灌胃给药24周后,本发明药物对动物的一般状况、血液学指标、血液生化指标均无明显的影响,系统解剖、脏器系数及组织病理学检查也未发现异常病理改变。停药2周也未见明显改变。结果表明:本发明西药组合物在长期毒性试验中,未发现明显毒性反应和延迟毒性反应。可见,本发明西药组合物无毒性反应,长期用药安全可靠。
3、临床试验
诊断标准:急性腹泻在临床上除腹泻外,一般都有发热、腹痛及白细胞增多等表现,主要表现为恶心、呕吐、腹痛、腹泻、发热等,严重者可致脱水、电解质紊乱、休克等,病人多表现为恶心、呕吐在先,继以腹泻,每日三至五次甚至数十次不等,大便多呈水样,深黄色或带绿色,恶臭,可伴有腹部绞痛、发热、全身酸痛等症状。收治67例患者,其中,男性42例,女性25例。
给予本发明实施例3制备的西药组合物,按照2mg/kg/次,2小时为一疗程并进行症状随访记录;疗效评定标准:显效:急性腹泻症状痊愈,恢复正常;好转:急性腹泻病变症状减轻,病情逐步好转;无效:达不到好转标准者。
治疗结果:67例患者经过一个疗程,61例痊愈,3例显效,3例好转,0例无效,总有效率100.0%;3例显效和3例好转患者再经过一个疗程全部痊愈。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (6)
1.一种治疗急性腹泻的西药组合物,其特征在于,按照重量份的主要原料为:咖啡酸甲酯8-12份、苦瓜苷A 15-19份、白芥子苷3-8份、地黄苷7-12份、次水杨酸铋0.5-0.7份、甲氟哌酸6-9份、去甲基川陈皮素16-22份、去甲基蟛蜞内酯7-15份、石蒜碱盐酸盐2-4份、异莪术烯醇2-4份、3-氢化去氢松苓酸2-4份、灵芝酸C62-4份、异银杏素5-10份。
2.根据权利要求1所述的治疗急性腹泻的西药组合物,其特征在于,所述治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯9-11份、苦瓜苷A 16-18份、白芥子苷5-7份、地黄苷8-11份、次水杨酸铋0.5-0.7份、甲氟哌酸6-9份、去甲基川陈皮素18-21份、去甲基蟛蜞内酯8-12份、石蒜碱盐酸盐2-4份、异莪术烯醇2-4份、3-氢化去氢松苓酸2-4份、灵芝酸C62-4份、异银杏素6-8份。
3.根据权利要求1或2所述的治疗急性腹泻的西药组合物,其特征在于,所述治疗急性腹泻的西药组合物,按照重量份的主要原料为:咖啡酸甲酯10份、苦瓜苷A 17份、白芥子苷6份、地黄苷10份、次水杨酸铋0.6份、甲氟哌酸8份、去甲基川陈皮素20份、去甲基蟛蜞内酯10份、石蒜碱盐酸盐3份、异莪术烯醇3份、3-氢化去氢松苓酸3份、灵芝酸C63份、异银杏素7份。
4.一种如权利要求1-3任一所述的治疗急性腹泻的西药组合物的制备方法,其特征在于,具体步骤为:
首先,在医药级洁净区内,按上述计量比称取咖啡酸甲酯、苦瓜苷A、白芥子苷、地黄苷、次水杨酸铋、甲氟哌酸、去甲基川陈皮素、去甲基蟛蜞内酯、石蒜碱盐酸盐、异莪术烯醇、3-氢化去氢松苓酸、灵芝酸C6、异银杏素,过筛,机械混匀后添加超纯水,放置制药混合机中,混合4-8min,控制RSD≤5%,混合后压片并低温干燥,温度控制在4-8℃,包装即得治疗急性腹泻的西药组合物。
5.根据权利要求4所述的治疗急性腹泻的西药组合物的制备方法,其特征在于,具体步骤中混合6min。
6.根据权利要求4所述的治疗急性腹泻的西药组合物的制备方法,其特征在于,具体步骤中温度控制在6℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611171780.1A CN106822133A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗急性腹泻的西药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611171780.1A CN106822133A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗急性腹泻的西药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106822133A true CN106822133A (zh) | 2017-06-13 |
Family
ID=59139508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611171780.1A Withdrawn CN106822133A (zh) | 2016-12-17 | 2016-12-17 | 一种治疗急性腹泻的西药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106822133A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111658633A (zh) * | 2020-06-10 | 2020-09-15 | 大连天星本草生物科技有限公司 | 一种双黄酮化合物在制备抑制人羧酸酯酶2的药物和/或药物组合物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728145A (zh) * | 2016-12-17 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗急性腹泻的中西药组合物及其制备方法 |
-
2016
- 2016-12-17 CN CN201611171780.1A patent/CN106822133A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728145A (zh) * | 2016-12-17 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗急性腹泻的中西药组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
BISERKA TROSELJ-VUKIC等: "Efficacy of Pefloxacin in the Treatment of Patients with Acute Infectious Diarrhoea", 《CLIN DRUG INVEST》 * |
R. VANHOOF等: "The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms", 《INFECTION》 * |
马秀阁等: "培氟沙星治疗顽固性细菌性痢疾临床观察", 《中原医刊》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111658633A (zh) * | 2020-06-10 | 2020-09-15 | 大连天星本草生物科技有限公司 | 一种双黄酮化合物在制备抑制人羧酸酯酶2的药物和/或药物组合物中的应用 |
CN111658633B (zh) * | 2020-06-10 | 2023-12-22 | 大连天星本草生物科技有限公司 | 一种双黄酮化合物在制备抑制人羧酸酯酶2的药物和/或药物组合物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019220335A1 (en) | Compositions for use in the treatment of obesity | |
CN106728145A (zh) | 一种治疗急性腹泻的中西药组合物及其制备方法 | |
CN105902558B (zh) | 一种药物组合物及其制备方法和应用 | |
CN106822133A (zh) | 一种治疗急性腹泻的西药组合物 | |
CN111265599A (zh) | 番茄红素和葡萄籽组合物在制备治疗关节炎药物中的应用 | |
JP2021518852A (ja) | 心血管疾患又は脳血管疾患を治療する漢方薬組成物及びその調製方法並びに使用 | |
CN101095868A (zh) | 一种治疗结肠炎的药物组合物及其制备方法 | |
CN107028944A (zh) | 一种治疗痛风的西药组合物及其应用 | |
CN103181945B (zh) | 丝瓜子的用途 | |
CN101548990B (zh) | 一种治疗小儿腹泻病的药物粉剂 | |
JP2010168399A (ja) | 血糖の上昇を抑制するための薬剤 | |
CN104587069A (zh) | 一种治疗痔疮的中药制剂 | |
CN106913669A (zh) | 一种治疗胰腺炎的中药组合物及其应用 | |
CN106540119B (zh) | 复方木尼孜其药物组合物在制备镇痛药物中的用途 | |
CN115607588B (zh) | 一种标本兼治抗痛风的芹槐提取物与非布司他药物组合物及其用途 | |
Deogade et al. | Moringa oleifera Lam. Enriched Biscuits Induced Adverse Drug Reaction-a Case Report | |
CN102698144B (zh) | 一种治疗胃胀的中药组合物 | |
CN103191170B (zh) | 一种辅助治疗2型糖尿病的保健品及其制备方法 | |
CN101401903A (zh) | 一种治疗奶牛子宫内膜炎的中药组合物 | |
CN1248697C (zh) | 一种治疗慢性肠炎的药物组合物及其制备方法 | |
CN106668600A (zh) | 一种治疗慢性肾小球炎的复合制剂 | |
CN106727508A (zh) | 一种治疗慢性痢疾的复合药物 | |
CN106728042A (zh) | 一种治疗细菌性痢疾的复合药物 | |
CN117838823A (zh) | 一种中药组合物及其制备方法与应用 | |
CN115040576A (zh) | 一种治疗急性胰腺炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170613 |
|
WW01 | Invention patent application withdrawn after publication |